Itraconazole Safety Profile

Abstract

During the period 1984-1989, 11O patients with systemic and subcutaneous mycoses were treated with a new Imidazole derivative (ltraconazole, ITZ); 44 patients had paracoccidioidomycosis, 34 sporotrichosis, 18 chromoblastomycosis and 14 pulmonary aspergilloma. According to the severity of the disease, ITZ was administered at dosis of 100 mg/day (89 cases) or of 200 mg/day (21 cases). The mean duration of therapy was 18 months In ASP, 13 in CMB, 7 in PCM and 5 in SPT. ITZ was well tolerated and only 6.3%of the patients complained of minor gastric Intolerance. The hematological and hepatic function tests remained within normal limits in all patients, even those patients who showed hepatic dysfunction pretheray, improved during treatment with ITZ. The results of this study Indicated that this new triazole derivative is safe even when administered for prolonged periods.